The SUNEVO (GETNE-1408) trial to evaluate the activity and safety of thecombination of sunitinib with evofosfamide (TH-302) in patients with G1/G2 metastatic pancreatic neuroendocrine tumours (pNETs) naïve forsystemic treatment: A phase II study of the Spanish Task Force Group for Neuroendocrine and Endocrine Tumors (GETNE).

Authors

Enrique Grande

MD Anderson Cancer Center Madrid, Madrid, Spain

Enrique Grande , Carlos Lopez , Teresa Alonso-Gordoa , Marta Benavent , Jaume Capdevila , Alex Teule , Ana Custodio , Isabel Sevilla , Pablo Gajate , Javier Molina-Cerrillo , Jorge Hernando-Cubero , Rocio Garcia-Carbonero

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Sign-In

Similar Posters

insert_chart_outlined

Poster

2016 Gastrointestinal Cancers Symposium

bookmark_border

A phase II trial to assess the activity and safety of the hypoxia-activated prodrug evofosfamide (TH-302) in combination with sunitinib in patients with disseminated grade 1 and 2 pancreatic neuroendocrine tumors (pNET) as a first-line approach: The GETNE-1408 trial.

First Author: Enrique Grande

insert_chart_outlined

Poster

2022 ASCO Annual Meeting

bookmark_border

Randomized phase II study of adjuvant sunitinib or valproic acid in high-risk patients with uveal melanoma: The final analysis of cohort 1.

First Author: Rino S. Seedor

insert_chart_outlined

Poster

2017 ASCO Annual Meeting

bookmark_border

Phase II study of individualized sunitinib (SUN) as first-line therapy for metastatic renal cell cancer.

First Author: Georg A. Bjarnason

insert_chart_outlined

Poster

2017 Gastrointestinal Cancers Symposium

bookmark_border

Phase II study of intraperitoneal paclitaxel plus S-1/paclitaxel for gastric cancer with positive peritoneal cytology: CY-PHOENIX trial.

First Author: Masaki Aizawa